| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
ORIGINAL PAPER |
Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas, USA
Correspondence: Helen E. Heslop, M.D., Center for Cell and Gene Therapy, Baylor College of Medicine, 1102 Bates Street, Suite 1140, Houston, Texas 77030, USA. Telephone: 832-824-4662; Fax: 832-825-4668; e-mail: hheslop{at}bcm.tmc.edu
Latent Epstein-Barr virus (EBV) infection is associated with several malignancies, including Burkitts lymphoma, Hodgkins disease, nasopharyngeal carcinoma, and post-transplant lymphoproliferative disease (LPD). The presence of EBV antigens in these tumors provides a target for immunotherapy approaches, and immunotherapy with EBV-specific cytotoxic T cells (CTLs) has proved effective in post-transplant LPDs, which are highly immunogenic tumors expressing type III latency. The malignant cells in Hodgkins disease and nasopharyngeal carcinoma express type II latency and hence a more restricted pattern of EBV antigens. Trials with autologous EBV-specific CTL responses are under way in both of these diseases, and while some activity has been seen, no patient has yet been cured. This reduced CTL efficacy may reflect either downregulation of immunodominant EBV proteins, which are major CTL targets, or the ability of these tumors to evade the immune response by secreting inhibitory cytokines. Further improvement of EBV-specific CTL therapy for these type II latency tumors will require improved methods to activate and expand CTLs specific for the subdominant EBV genes expressed and to genetically modify the expanded CTLs to render them resistant to inhibitory cytokines. If these strategies to improve the therapeutic potential of immunotherapy for EBV-associated tumors prove successful, this type of treatment may be adapted to other tumors expressing known (viral) antigens.
This article has been cited by other articles:
![]() |
A. Carbone, A. Gloghini, and G. Dotti EBV-Associated Lymphoproliferative Disorders: Classification and Treatment Oncologist, May 1, 2008; 13(5): 577 - 585. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Mrazek, S. B. Kreutmayer, F. A. Grasser, N. Polacek, and A. Huttenhofer Subtractive hybridization identifies novel differentially expressed ncRNA species in EBV-infected human B cells Nucleic Acids Res., May 11, 2007; 35(10): e73 - e73. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. R. Kincaid, L. S. Nield, R. S. Moore, and F. G. Keller Posttransplant Lymphoproliferative Disease: A Case Report and Review for the General Pediatrician Clinical Pediatrics, May 1, 2007; 46(4): 287 - 291. [Abstract] [PDF] |
||||
| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| THE ONCOLOGIST | STEM CELLS | CME | ALPHAMED PRESS JOURNALS |